Point Mutations of the c-H- ras Gene in Spontaneous Liver Tumors of Transgenic Mice Carrying the Human c-H- ras Gene

Abstract

Spontaneous proliferative liver lesions were found in 15 (13 males and 2 females) of 244 (122 of each sex) transgenic (Tg) mice carrying the human prototype c-H-ras gene (rasH2). The liver lesions included 3 foci of cellular alteration, 1 hepatocellular adenoma, 5 hepatocellular carcinomas, and 4 hepatic hemangiosarcomas in the males and 1 focus of cellular alteration and 1 hepatocellular carcinoma in the females. The mutation patterns of the human and endogenous mouse c-H-ras codon 61 in these proliferative liver lesions were analyzed by DNA amplification using polymerase chain reaction, single-strand conformation polymorphism (PCR-SSCP), and oligonucleotide dot blot hybridization. The hepatocellular carcinomas in 4 males and 1 female contained a point mutation in the mouse c-H-ras gene: 3, 1, and 1 carcinomas had a CAA to AAA transversion at the first base of codon 61, a CAA to CTA transversion, and a CAA to CGA transition at the second base of codon 61, respectively. No point mutations in the human c-H-ras transgene were detected in any hepatocellular carcinoma. All 4 hepatic hemangiosarcomas had a CAG to CTG transversion at codon 61 of the human c-H-ras gene, but no point mutations were detected in codon 61 of the mouse c-H-ras gene. No mutations in human or mouse c-H-ras codon 61 were detected in altered cell foci or hepatocellular adenoma. These results indicate that spontaneous liver tumors in rasH2 Tg mice contain different mutation patterns depending on the histologic type or cell origin of the tumors (i.e., hepatocellular carcinomas or hepatic hemangiosarcomas). The absence of similar mutations in foci of cellular alteration and the hepatocellular adenoma suggests that the occurrence of codon 61 point mutations is a late event in the progression of hepatocellular neoplasia in rasH2 Tg mice.

Keywords

Human prototype c-H-ras transgenic (rasH2 Tg)mouse hepatocellular carcinoma hepatic hemangiosarcoma polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP)nonradioactive oligonucleotide dot blot hybridization

References

1. Ando K , Saitoh A , Hino O , Takahashi R , Kimura M , and Katsuki M (1992). Chemically induced forestomach papillomas in transgenic mice carry mutant human c-H-ras transgenes. Cancer Res.. 52: 978–982.

2. Contrera JF , Jacobs C , and DeGeorge JJ (1997). Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul. Toxicol. Pharmacol.. 25: 130–145.

3. Davies TS and Monro A (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. J. Am. Coll. Toxicol.. 14: 90–107.

4. Doi ST , Kimura M , and Katsuki M (1994). Site-specific mutation of the human c-H-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice. Jpn. J. Cancer Res.. 85: 801–807.

5. Faccini JM , Butler WR , Friedmann JC , Hess R , Reznik GK , Ito N , Hayashi Y , and Williams GM (1992). IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bio-assay. Exp. Toxicol. Pathol.. 44: 443–456.

6. Fox TR , Schumann AM , Watanabe PG , Yano BL , Maher VM , and McCormick JJ (1990). Mutational analysis of the H-ras oncogene in spontaneous C57BL/6 X C3H/He mouse liver tumors and tumors induced with genotoxic and nongenotoxic hepatocarcinogens. Cancer Res.. 50: 4014–4019.

7. Frith CH , Ward JM , and Turusov VS (1994). Tumours of the liver. In: Pathology of Tumours in Laboratory Animals, 2nd ed., VS Turusov and U Mohr (eds). IARC Scientific Publications, Lyon, France, pp. 223–269.

8. Inoue R , Ushijima T , Katami M , Kushida H , Wakabayashi K , Sato H , Asamoto M , Katsuki M , Sugimura T , and Nagao M (1996). Rare activation of the human c-H-ras transgene of mice in hemangioen-dothelial sarcomas and liver tumors induced by Glu-P-1. Jpn. J. Cancer Res.. 87: 583–588.

9. Ito N , Hasegawa R , Imaida K , Hirose M , Shirai T , Tamano S , and Hagiwara A (1997). Medium-term rat liver bioassay for rapid detection of hepatocarcinogenic substances. J. Toxicol. Pathol.. 10: 1–11.

10.

10. Lai DY , Baetcke KP , Vu VT , Cotruvo JC , and Eustis SL (1994). Evaluation of reduced protocols for carcinogenicity testing of chemicals: Report of a joint EPA/NIEHS workshop. Regul. Toxicol. Pharmacol.. 19: 183–201.

11.

11. Maronpot RR , Fox T , Malarkey DE , and Goldsworthy TL (1995). Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology. 101: 125–156.

12.

12. Maronpot RR , Haseman JK , Boorman GA , Eustis SE , Rao GN , and Huff JE (1987). Liver lesions in B6C3F1 mice: The National Toxicology Program, experience and position. Arch. Toxicol. Suppl 10: 10–26.

13.

13. Ogawa K , Imaida K , Masui T , Kawabe M , Hasegawa R , Kato K , Ito N , and Shirai T (1996). Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of the human c-Ha-ras transgene. Carcinogenesis. 17: 341–345.

14.

14. Organization for Economic Cooperation and Development (1981). Guideline for Testing of Chemicals. Carcinogenicity Studies. Document 451.

15.

15. Richardson KK , Helvering LM , Copple DM , Rexroat MA , Linville DW , Engelhaedt JA , Todd GC , and Richardson FC (1992). Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and carcinomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979 to 1986. Carcinogenesis. 13: 935–941.

16.

16. Saiki RK , Gelfand DH , Stoffel S , Scharf SJ , Higuchi R , Horn GT , Mullis KB , and Erlich HA (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 239: 487–491.

17.

17. Saitoh A , Kimura M , Takahashi R , Yokoyama M. Nomura T , Izawa M. Sekiya T , Nishimura S , and Katsuki M (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene. 5: 1195–2000.

18.

18. Shibata D (1994). Extraction of DNA from paraffin-embedded tissue for analysis by polymerase chain reaction: New tricks from an old friend. Hum. Pathol.. 25: 561–563.

19.

19. Speid LH , Lumley CE , and Walker SR (1990). Harmonization of guidelines for toxicity testing of pharmaceuticals by 1992. Regul. Toxicol. Pharmacol. 12: 179–211.

20.

20. Stanley LA (1995). Molecular aspects of chemical carcinogenesis: The roles of oncogenes and tumour suppressor genes. Toxicology. 96: 173–194.

21.

21. Tennant RW , French JE , and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect.. 103: 942–950.

22.

22. Tsunematsu S , Saito H , Kagawa T , Morizane T , Hata I , Nakamura T , Ishii H , Tsuchiya M , Nomura T , and Katsuki M (1994). Hepatic tumors induced by carbon tetrachloride in transgenic mice carryinga human c-H-ras protooncogene without mutations. Int. J. Cancer. 59: 554–559.

23.

23. Tsunematsu S , Saito H , Tada S , Ebinuma H , Tsuchiya M , Kumagai N , Morizane T , Nomun T , and Ishii H (1997). Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene. J. Gastroeriterol. Heparol.. 12: 319–324.

24.

24. U.S. Environmental Protection Agency (1986). Guidelinesfor Carcinogen Risk Assessment. EPA/600/8-82/006F. US. Environmental Protection Agency, Washington, D.C.

25.

25. Vries MV , Bogaard ME , van den Elst H , van Boom JH , van der Eb AJ , and Bos JL (1986). A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. Gene. 50: 313–320.

26.

26. Yamamoto S , Hayashi Y , Mitsumori K , and Nomura T (1997). Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene. Lab. Anim. Sci.. 47: 121–126.

27.

27. Yamamoto S , Mitsumori K , Kodama Y , Matsunuma N , Manabe S , Okamiya H , Suzuki H , Fukuda T , Sakamaki Y , Sunaga M , Nomura, G , Hioki K , Wakana S , Nomura T , and Hayashi Y (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-H-ras gene than in control non-transgenic mice. Carcinogenesis. 17: 2455–2461.